Locally advanced breast cancer (LABC) has a poor prognosis with a high risk of local recurrence and distant metastasis. Preoperative combined chemotherapy with or without granulocyte colony-stimulating factor (G-CSF) support does not improve the long-term survival rate. In our report, two patients with LABC received preoperative high-dose chemotherapy with peripheral blood stem cell support (HDC/PBSCs). Prior to high-dose chemotherapy with peripheral blood stem cell support, they both received induction chemotherapy of cyclophosphamide, epirubicin and 5-fluorouracil (FEC) for two cycles which resulted in a partial response. PBSC mobilization and collection were carried out following the second cycle of induction chemotherapy followed by G-CSF. High-dose cyclophosphamide (2500 mg/m 2 ), carboplatin (600 mg/m 2 ) and etoposide (600 mg/m 2 ) were administered with PBSC support. A radical mastectomy was performed followed by adjuvant chemotherapy with FEC regimen for four cycles, followed by local irradiation, and endocrine therapy with tamoxifen. Both patients achieved a remarkable response in the primary lesion after HDC/PBSCs and tolerated the whole treatment well. Preoperative HDC/PBSCs as a new strategy in the treatment of LABC seems practical but it needs to be studied more deeply. Bone Marrow Transplantation (2001) 27, 345-346. Keywords: breast cancer; peripheral blood stem cell; high-dose chemotherapy High-dose chemotherapy with peripheral blood stem cell support for breast cancer has been developed for over 10 years on the basis of dose-response effects. In most clinical trials, high-dose chemotherapy with peripheral blood stem cell support is only used as a post-operative adjuvant chemotherapy for breast cancer with high risk and as a palliative therapy for metastatic breast cancer. No clinical trial of high-dose chemotherapy with peripheral blood stem cell
support as a primary management of locally advanced breast cancer (LABC) and other early-stage breast cancer with high risk before surgery has been reported.
LABC is a disease category defined by the shifting boundaries of an evolving tumor, node, metastasis (TNM) staging system and by the increasing exclusion of patients discovered to have distant metastasis by more sensitive diagnostic techniques. 1 We present two cases of female patients with LABC who received high-dose chemotherapy with peripheral blood stem cell support, followed by a radical mastectomy, post-operative chemotherapy for four cycles of FEC and locoregional radiation, and tamoxifen. After high-dose chemotherapy with peripheral blood stem cell support, a remarkable regression was observed in the primary lesions of the two patients with both patients tolerating the whole treatment process well.
Case reports
Two female patients with primary LABC characterized by large primary lesions of breast and axillary lymph node metastasis were admitted into our hospital. The first patient was a 29-year-old-lactative female with a 11 ϫ 10.5 ϫ 5 cm primary lesion and a 3 ϫ 3 ϫ 4 cm fixed lymph node. The other was a 52-year-old menopausal female with two primary lesions 3 ϫ 3.5 ϫ 3 cm and 2.5 ϫ 2 ϫ 2 cm, and one fixed lymph node 3 ϫ 2 ϫ 3 cm. Tumor size was measured by chest computed tomography (CT) and by two independent observers in our hospital. A fine needle biopsy was taken under ultrasound in the primary lesions of the two patients and diagnosed as malignant cells by experienced cytologists. Complete blood cell count, hepatic and renal function tests, electrocardiogram and echocardiograph were all in the normal range. Whole body bone scan, chest and abdominal CT and bone marrow aspiration showed no evidence of distant metastatic disease. DNA flow cytometry of bone marrow cells in both cases showed diploid DNA.
After two cycles of FEC induction chemotherapy consisting of cyclophosphamide (600 mg/m 2 ), epirubicin (100 mg/m 2 ) and 5-fluorouracil (500 mg/m 2 ) with G-CSF support, a partial response was achieved in both patients. In the first patient, the 11 ϫ 10.5 ϫ 5 cm primary lesion was reduced to 6 ϫ 5 ϫ 3.5 cm and the 3 ϫ 3 ϫ 4 cm lymph node to 1.6 ϫ 1.8 ϫ 2 cm. In the second patient, one primary lesion 3 ϫ 3.5 ϫ 3 cm was reduced to 1.5 ϫ 1.7 ϫ 1.5 cm and the other 2.5 ϫ 2 ϫ 2 cm to 1.0 ϫ 1.0 ϫ 1.3 cm, and a metastatic 3 ϫ 2 ϫ 3 cm lymph node was reduced to 1 ϫ 1 ϫ 1.5 cm.
PBSC mobilization was started with G-CSF (2.5 g/kg) twice daily from day 7 after the start of the second cycle of induction chemotherapy. PBSC were collected and cryopreserved on day 11 and day 12. The high-dose chemotherapy consisted of cyclophosphamide (2500 mg/m ϩ cells were infused into the two patients. G-CSF(5 g/kg/day) was administered from day 3 until the WBC was higher than 2 ϫ 10 9 /l. Rapid recovery of bone marrow function was observed in both patients. The granulocytes exceeded 0.5 ϫ 10 9 /l on day 10 and 11, and platelets exceeded 50 ϫ 10 9 /l on days 12 and 15 in the two patients, respectively. Both patients tolerated the high-dose chemotherapy and transplant procedure well.
Three weeks after high-dose chemotherapy, all investigations were repeated and no abnormal results were found. In the first patient, the primary lesion decreased from 6 ϫ 5 ϫ 3.5 cm to 2 ϫ 2.5 ϫ 2 cm and the lymph node from 1.6 ϫ 1.8 ϫ 2 cm to 0.6 ϫ 0.8 ϫ 1.0 cm. In the second patient, one primary lesion decreased from 1.5 ϫ 1.7 ϫ 1.5 cm to 0.8 ϫ 0.8 ϫ 0.5 cm and the other from 1.0 ϫ 1.0 ϫ 1.3 cm to unmeasurable, and the lymph node decreased from 1 ϫ 1 ϫ 1.5 cm to unmeasurable. Four weeks after HDC/PBSCs, both patients underwent radical mastectomy. Histopathology showed infiltrative ductal carcinoma with degeneration of tumor cells in both patients. The first patient had four of 11 positive lymph nodes with positive estrogen receptor (ER) and progesterone receptor (PR), and positive c-erb-b-2. The other had four of 12 positive lymph nodes with negative ER, PR, and c-erb-b-2. Four weeks after operation, four cycles of FEC chemotherapy were given with G-CSF support followed by tamoxifen (10 mg twice a day) and locoregional radiation (5000 cGy in a total of 25 fractions). Currently, the 29-year-old patient has been disease free for 15 months and the 52-year-old one for 13 months.
Discussion
LABC is a very common clinical presentation of breast cancer in developing countries (30% to 60%) 2 and the 5-and 10-year survival rates for these patients are still very low and vary from 10% to 40% and from 0% to 30%, respectively. 2 One of the primary therapies of LABC used clinically is preoperative chemotherapy also called neoadjuvant chemotherapy which has the advantage of reducing primary tumor burden and preventing distant recurrence after operation. However, even though preoperative chemotherapy resulted in high rates of short-term response and changed the natural history of LABC, there is no apparent improvement in long-term survival. [3] [4] [5] One of the main reasons may be due to the low-dose intensity used in most trials. HDC/PBSCs prior to surgery may increase dose intensity of chemotherapy and effect in the management of LABC. In our hospital, we used HDC/PBSCs as a primary therapy of LABC, to evaluate the probability, effect and toxicity of this new strategy in the therapy of LABC in two patients. The protocol included induction chemotherapy with two cycles of FEC (followed by PBSC mobilization and collection), HDC/PBSCs, radical mastectomy, postoperative chemotherapy with four cycles of FEC locoregional radiation, and endocrine therapy with tamoxifen. As the success of HDC/PBSCs depend on the tumor burden and the sensitivity of the breast cancer cells to chemotherapy, we performed induction chemotherapy for two cycles of FEC before administration of HDC/PBSCs to reduce the tumor burden and test the sensitivity of cancer cells. We found that wound healing was not affected by preoperative HDC/PBSCs after radical mastectomy. The patients tolerated the whole protocol well. Recent randomized phase III results of HDC/PBSCs in the management of metastatic breast cancer and high-risk breast cancer for recurrence showed that there is no significant difference in the longterm survival. [6] [7] [8] [9] This led us to believe the timing of HDC/PBSCs in the management of breast cancer is more important. We may need to know first what is better using preoperative HDC/PBSCs as a primary treatment, or postoperatively as an adjuvant therapy or in advanced stage. HDC/PBSCs may have a important role in the preoperative management of breast cancer with high risk. Our experience in the management of these two patients with LABC suggested that HDC/PBSCs is safe and tolerable, and may be an effective way to handle the LABC and other earlystage breast cancers with poor prognosis. To evaluate the effect of this new strategy of HDC/PBSCs as a primary therapy of LABC, more patients with LABC are needed and should be followed-up for a longer time.
